|
| Status |
Public on Mar 18, 2015 |
| Title |
DOHH2_ITF-A_exp2 |
| Sample type |
RNA |
| |
|
| Source name |
DOHH2 cell lines treated with ITF-A
|
| Organism |
Homo sapiens |
| Characteristics |
cell line: DOHH2
treatment: ITF-A
|
| Treatment protocol |
treatment with ITF-A or ITF-B, a HDAC inhibitor.
treatment with OTX015, a BET Bromodomain inhibitor.
|
| Growth protocol |
in vitro
in vitro
|
| Extracted molecule |
total RNA |
| Extraction protocol |
RNA extraction was performed using a commercially available kit (RNeasy, Qiagen, Frederick,MD) according to the manufactures’ recommendations. RNA quality was confirmed based on a RNA integrity number >8 by use of an electrophoresis bioanalyzer (2100 Agilent Bioanalyser).
RNA extraction was performed using a commercially available kit (RNeasy, Qiagen, Frederick,MD) according to the manufactures’ recommendations. RNA quality was confirmed based on a RNA integrity number >8 by use of an electrophoresis bioanalyzer (2100 Agilent Bioanalyser).
|
| Label |
biotin
|
| Label protocol |
Biotinylated cRNA were prepared with the Ambion TotalPrep RNA Amplification Kit for Illumina arrays
Biotinylated cRNA were prepared with the Ambion TotalPrep RNA Amplification Kit for Illumina arrays
|
| |
|
| Hybridization protocol |
Whole Genome Gene Expression Direct Hybridization
Whole Genome Gene Expression Direct Hybridization
|
| Scan protocol |
Illumina HiScan
Illumina HiScan
|
| Description |
9373549125_H
|
| Data processing |
The data were normalised using quantile method
The data were normalised using quantile method
|
| |
|
| Submission date |
Jan 09, 2015 |
| Last update date |
Mar 18, 2015 |
| Contact name |
Francesco Bertoni |
| E-mail(s) |
[email protected]
|
| Phone |
+41 91 820 0367
|
| Organization name |
IOR
|
| Department |
Lymphoma & Genomics Research Program
|
| Street address |
Via V. Vela 6
|
| City |
Bellinzona |
| State/province |
Ticino |
| ZIP/Postal code |
6500 |
| Country |
Switzerland |
| |
|
| Platform ID |
GPL10558 |
| Series (1) |
| GSE64821 |
Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response |
|
